The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.

William James famously wrote, “Everyone knows what attention is”. Yet cognitive scientists are still struggling to come up with a clear definition of attention. The same might be said of confidence.